Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Radiation.

UCLA School of Medicine, Los Angeles, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Los Angeles, CA
Treatments:RadiationHospital:UCLA School of Medicine
Drugs:Journal:Link
Date:Nov 2007

Description:

Patients: This phase I study involved 33 patients with glioblastoma multiforme. The median age of these patients was 51, ranging from 23-72 years old. Twenty-one patients were men and twelve were women.

Treatment: Patients were treated with motexafin gadolinium and radiotherapy. Motexafin gadolinium accumulates (is gathered up by) in tumor cells, causes death of cells, and it can be seen during an MRI. Therefore, giving this treatment before the patient receives radiation may make the radiotherapy more effective, since the tumor cells will be easier to see and be targeted.

Toxicity: A grade 3 increase in serum alanine aminotransferase was reported. Grade 1 and 2 toxicities included headache, vasodilatation, skin discoloration, urine discoloration, rash/photosensitivity, and gastrointestinal symptoms.

Results: The median overall survival was17.6 months. The data collected was then calculated differently, in a case-matched analysis, and the median overall survival was 16.1 months.

Support: Research funds were provided by Pharmacyclics, which developed motexafin gadolinium.

Correspondence: Dr. Judith M. Ford





Back